David R K Harding
Massey University, New Zealand
Title: Heating enhancement efficiency of magnetic iron oxide (Fe3 O4 ) nanoparticles for magnetic fluid hyperthermia applications (anti-cancer theraphy)
Biography
Biography: David R K Harding
Abstract
Magnetic Fluid Hyperthermia (MFH) has been proposed as a potential non-invasive technique for cancer treatment due to its markedly low side effects compared to conventional radiotherapy or chemotherapy. It is based on conversion of electromagnetic energy into heat by super paramagnetic iron oxide (Fe3O4) Nanoparticles (NPs). The current clinical system comprises Fe3O4 NPs coated with aminosilane which has obtained clinical approval in the European Union (2009) and has been tested on patients with prostate carcinoma and glioblastoma multiforme. There are however some critical challenges associated with the current clinical system such as low magnetization and low induction heating power (Specific Absorption Rate; SAR) at a biological safe range of induced magnetic field and its non-targeting nature which makes it inapplicable for treatment of deep-seated tumors.